Clinical Research Directory
Browse clinical research sites, groups, and studies.
Olanzapine for Cancer Related Anorexia-cachexia Syndrome
Sponsor: Mahidol University
Summary
Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.
Official title: Randomized Placebo-controlled Study of Olanzapine for Cancer Related Anorexia-cachexia Syndrome
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
138
Start Date
2024-01-22
Completion Date
2026-01-21
Last Updated
2024-07-24
Healthy Volunteers
No
Interventions
Olanzapine 2.5 MG
olanzapine 2.5 mg/day for 28 days
Olanzapine 5 MG
olanzapine 5 mg/day for 28 days
Placebo
placebo 1 tab/day for 28 days
Locations (2)
Faculty of Medicine Siriraj Hospital
Bangkok, Thailand
Division of medical oncology, department of medicine Siriraj Hospital
Bangkok, Thailand